All Transactions - Bryan, Garnier & Co

Our transactions

Bryan, Garnier & Co offers a complete range of investment banking services, from growth financing to mergers and acquisitions.

Bryan, Garnier & Co acts as European Lead Manager to Humanigen on its USD 92.5 million Marketed Follow-on Offering

Bryan, Garnier & Co acts as Joint Global Coordinator & Joint Bookrunner to LMK Group on its SEK 500 million Initial Public Offering

LMK_Group_website_tombstone

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner to GenSight on its EUR 30 million Follow-on Offering

GenSight_2021_website_tombstone

Bryan, Garnier & Co acts as Joint Bookrunner to Azelio on its SEK 596 million Follow-on Offering

Azelio_website_tombstone_march2021

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner to Basilea Pharmaceutica on its CHF 46 million Follow-on Offering

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner to MedinCell on its EUR 30 million Follow-on Offering

Medincell_website_tombstone

Bryan, Garnier & Co helps Zealand Pharma raise DKK 749 million from the global capital markets via an accelerated bookbuild

Zealand_Pharma_tombstone

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner to Nicox on its EUR 15 million Follow-on Offering

Nicox_website_tombstone

Bryan, Garnier & Co acts as Sole Global Coordinator and Sole Bookrunner to Proparco on its EUR 23 million Secondary Offering of Voltalia shares

Voltalia_website_tombstone

Bryan, Garnier & Co acts as Sole Global Coordinator and Sole Bookrunner to Abivax on its EUR 28 million Follow-on Offering

Abivax_website_tombstone

Bryan, Garnier & Co acts as Joint Bookrunner to GenSight on its EUR 25 million Follow-on Offering

Tombstone_gensight

Bryan, Garnier & Co acts as Joint Bookrunner to Targovax on its NOK 75 million Follow-on Offering

Bryan, Garnier & Co acts as Sole Financial Advisor, Sole Global Coordinator and Sole Bookrunner to McPhy on a EUR 180m Follow-on Offering including Strategic Investments from Chart Industries and Technip Energies

McPhy_website_tombstone_4

Bryan, Garnier & Co acts as Joint Bookrunner on Sensorion’s EUR 31 million Follow-on Offering with top tier US and European biotech specialists and institutional investors

website_tombstone_2

Bryan, Garnier & Co acts as European Lead Manager to Humanigen on its USD 78 million Follow-on Offering

tombstone_humanigen_78200000_dollars

Bryan, Garnier & Co acts as Joint Bookrunner to Azelio on its SEK 270 million Follow-on Offering

Azelio tombstone 2

Bryan, Garnier & Co acts as Co-manager to BioNTech on its USD511.5 million upsized Publicly-marketed Follow-on Offering

BioNTech_website_tombstone

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner to Carbios on its EUR 37 million upsized Follow-on Offering

Carbios website tombstone

Bryan, Garnier & Co acts as Sole Global Coordinator on a EUR 7.3 million Rights Issue for medtech company Pixium Vision

Pixium_website_tombstone

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner on MedinCell’s Follow-on with top-tier European biotech specialists and institutional investors

Medincell_website_tombstone

Bryan Garnier & Co acts as Joint Bookrunner and Joint Broker to AIM-listed 4D Pharma on its GBP 22 million equity Fund Raising

4Dpharma_website_tombstone

Bryan, Garnier & Co acts as Sole Bookrunner on GeNeuro EUR17.5 million Private Placement

GeNeuro_website_tombstone

Bryan, Garnier & Co accompanies DBV on its USD 143 million NASDAQ Follow-on

DBV_website_tombstone_2019

Bryan, Garnier & Co acts as Joint Bookrunner to BioNTech on its USD 150 million Nasdaq Initial Public Offering

Biontech_website_tombstone

Bryan, Garnier & Co acts as Joint Bookrunning Manager on Celyad’s USD 20 million global equity offering

Celyad_website_tombstone

Bryan, Garnier & Co acts as Sole Bookrunner on Carbios EUR 14.5million Private Placement

Carbios_website_tombstone

Bryan, Garnier & Co acts as Joint Bookrunner to Genfit on its $155.4 million Nasdaq Initial Public Offering

Genfit tombstone

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner for MedinCell’s €30 million Euronext Paris IPO

MedinCell tombstone

Bryan, Garnier & Co acts as Joint Bookrunner on Materialise’s USD45 million Follow–On Equity Offering on Nasdaq

Materialise tombstone

Bryan, Garnier & Co acts as Sole Bookrunner on ASIT biotech EUR12 million Convertible Bond Placement

ASIT biotech tombstone

Bryan, Garnier & Co acts as Co-manager on Canopy Growth’s benchmark CAD600 million Convertible Bond New Issue

Canopy_2018_tombstone

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner for Voluntis’ IPO, the first ever listing of a digital therapeutics company raising EUR30.1 million

Voluntis tombstone

Bryan, Garnier & Co acts as Lead Manager on Medigene’s EUR48.3 million offering

Medigene tombstone

Bryan, Garnier & Co acts as Joint Global Coordinator on Celyad’s EUR46.1 million global equity offering

Celyad tombstone

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner for Medartis’ IPO CHF142.6 million on SIX Swiss Exchange

Medartis tombstone

Bryan, Garnier & Co part of bulge bracket syndicate for DBV $150 million Follow-on

DBV tombstone

Bryan, Garnier & Co advises Bone Therapeutics on its €19.45 million convertible bond placement

Bone Therapeutics tombstone

Bryan Garnier & Co acts as Global Coordinator for Biom’Up’s financing representing a total amount of more than €40 million

BiomUp tombstone

Bryan, Garnier & Co acts as Co-manager for Ablynx Nasdaq IPO raising USD 230 million

Ablynx tombstone

Bryan Garnier & Co acts as Sole Global Coordinator for Biom’Up’s landmark Euronext IPO, raising up to €44 million including greenshoe

BiomUp_Oct_17 tombstone

Bryan, Garnier & Co acts as Joint Bookrunner of a private placement with US and European Investors raising €18 Million for Oryzon

Oryzon tombstone

Upon pricing its landmark IPO on Euronext Paris led by Sole Global Coordinator Bryan, Garnier & Co, Symetis is acquired by Boston Scientific for USD 435 million

Symetis tombstone

Bryan, Garnier & Co announces the successful USD 22 million / DKK 143 million follow-on offering for Zealand Pharma

Zealand tombstone

Bryan, Garnier & Co annouces the successful closing of Soitec’s €75.4 million Rights Issue

Soitec tombstone

Rights Issue Sandnes Sparebank ASA

Sandes Sparebank_jun16

Bryan, Garnier & Co announces a €14.7m follow-on offering for Amoeba on Euronext with demand from European and US investors

Amoeba tombstone

Bryan Garnier & Co advises GeNeuro on its Euronext IPO, raising €33 million, acting as Global Coordinator & Joint Bookrunner

GeNeuro tombstone

Equity Issue SparebankenVest AS

SparebankenVest_tombstone_dec15

Bryan Garnier & Co advises DBV Technologies on its follow-on offering, raising $281.5m in July 2015, acting as financial advisor

DBV Technologies tombstone

Bryan, Garnier & Co announces the successful €13.2m Euronext IPO of Amoéba

Amoéba 2015